[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351122-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351122-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","evaluation-of-tramppf-nanoparticles-for-efficacy-against-pancreatic-cancer-in-mice-model","Evaluation of TRAM@PPF Nanoparticles for Efficacy Against Pancreatic Cancer in Mice Model","","Evaluation of TRAM@PPF nanoparticles examines targeted delivery for pancreatic ductal adenocarcinoma using a mouse model. The study supports the oncogenic relevance of KCa3.1 through TCGA and GTEx analyses and functional assays, then formulates PLGA nanoparticles modified with PEG2000-FA to deliver the KCa3.1 inhibitor TRAM-34. Physical characterization and release profiling precede in vitro and in vivo testing, showing enhanced uptake, inhibited proliferation, increased apoptosis, reduced tumor growth and weight, prolonged survival, and favorable biosafety, supporting further clinical translation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/evaluation-of-tramppf-nanoparticles-for-efficacy-against-pancreatic-cancer-in-mice-model/351122/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/evaluation-of-tramppf-nanoparticles-for-efficacy-against-pancreatic-cancer-in-mice-model/351122.png","ImageObject",300,407,{"name":42,"@type":43},"Miles","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-18","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address in pancreatic ductal adenocarcinoma treatment?","Question",{"text":63,"@type":64},"PDAC has limited effective therapies and a poor prognosis, largely because the dense desmoplastic tumor microenvironment obstructs drug delivery and supports rapid progression. The work targets this barrier by developing a targeted nanodrug system.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is TRAM@PPF designed to improve targeted delivery?",{"text":68,"@type":64},"TRAM@PPF uses PLGA nanoparticles modified with PEG2000-FA (folate) to deliver the KCa3.1 channel inhibitor TRAM-34, aiming for folate-mediated tumor targeting and improved uptake in PDAC cells.",{"name":70,"@type":61,"acceptedAnswer":71},"What efficacy outcomes are reported in vitro and in vivo?",{"text":72,"@type":64},"In vitro, TRAM@PPF inhibits cell proliferation and enhances apoptosis. After intravenous dosing in pancreatic cancer mouse models, it significantly reduces tumor growth and tumor weight and prolongs survival, while showing excellent biosafety.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351122,1792231327,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","International Journal of Nanomedicine  \n Open Access Full Text Article  \nORIGINAL RESEARCH  \nEvaluation of TRAM@PPF Nanoparticles for Efficacy Against Pancreatic Cancer in Mice Model  \nPing Sheng 1 , *, Liang Zhang2 , *, Wenwei Xie2 , *, Yu He 3 , *, Yanjiao Wu 1 , Jinyu Huang 3 , Dan Li 3 , Jiafu Leng4 , Debing Xiang 1  \n1Department of Oncology, Chongqing University Jiangjin Hospital, Chongqing, 402260, People’s Republic of China; 2School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People’s Republic of China; 3Chongqing University Cancer Hospital, School of Medicine, Chongqing University, Chongqing, 400044, People’s Republic of China; 4Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250012, People’s Republic of China  \n*These authors contributed equally to this work  \nCorrespondence: Debing Xiang, Departments of Oncology, Chongqing University Jiangjin Hospital, Chongqing, 402260, People’s Republic of China, [Email xdb86@cqu.edu.cn](Email xdb86@cqu.edu.cn); Jiafu Leng, Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250012, People’s Republic of China, Email [lengjiafu529@163.com](lengjiafu529@163.com)  \n\n| Introduction: Pancreatic ductal adenocarcinoma (PDAC) poses a major challenge due to the lack of effective treatment options and its extremely poor prognosis. Nanodrug delivery systems can improve drug solubility and enable efficient targeted delivery, offering new possibilities for PDAC therapy.\u003Cbr>Methods: The oncogenic role of KCa3.1 in PDAC was validated through analyses of The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases combined with functional assays. To overcome the limitations of conventional therapies, we developed a targeted nanodrug delivery system, TRAM@PPF, based on PLGA nanoparticles modified with polyethylene glycol-folate (PEG2000-FA) . This system was prepared by the emulsion-solvent evaporation method to specifically deliver the KCa3.1 channel inhibitor TRAM-34 to PDAC cells. We characterized the nanosystem’s physical properties and release profile and evaluated its antitumor efficacy in vitro and in vivo.\u003Cbr>Results: The synthesized TRAM@PPF nanoparticles demonstrated uniform size (~142 nm) and excellent stability, with superior cellular uptake compared to non-folate-modified nanoparticles. In vitro, TRAM@PPF showed potent antitumor activity by markedly inhibiting cell proliferation and enhancing apoptosis. Following intravenous administration in pancreatic cancer mouse models, TRAM@PPF significantly inhibited tumor growth, reduced tumor weight, and prolonged survival. Moreover, TRAM@PPF showed excellent biosafety in animal models, suggesting strong potential for further clinical translation in PDAC therapy.\u003Cbr>Conclusion: TRAM@PPF preserves folate-mediated tumor-targeting capability while significantly enhancing antitumor activity, offering a promising strategy for targeted therapy of pancreatic cancer.\u003Cbr>Keywords: nanoparticles, PDAC, KCa3.1 inhibitor |\n| --- |\n| Introduction\u003Cbr>Pancreatic cancer, often referred to as the “king of cancers” because of its extremely poor prognosis, is recognized as one of the most lethal tumors within the gastrointestinal system.1–3 The predominant form, pancreatic ductal adenocarcinoma (PDAC), is characterized by an exceptionally low 5-year survival rate and swift progression. A critical factor contributing to this poor prognosis is the unique tumor microenvironment (TME) of PDAC, which is defined by a dense, desmoplasticstroma composed of activated fibroblasts and excessive extracellular matrix. This fibrotic barrier not only promotes tumor cell survival but also creates high interstitial fluid pressure that collapses intratumoral blood vessels, significantly impeding the delivery of systemic therapies.4–7 Currently, treatment options for PDAC remain limited; mos","cbCaifYzt4DXYLmC","https://ap.wps.com/l/cbCaifYzt4DXYLmC","pdf",11800062,14,"English","# Introduction\n## Pancreatic cancer background and therapeutic challenges\n## Role of the KCa3.1 target and rationale for targeted nanodrug delivery\n# Methods\n## TCGA/GTEx validation and functional assays for KCa3.1\n## Nanoparticle formulation and characterization\n## In vitro and in vivo efficacy evaluation\n# Results\n## Nanoparticle size, stability, and cellular uptake\n## In vitro antitumor effects\n## In vivo tumor inhibition, tumor burden, survival, and biosafety\n# Conclusion\n## Preservation of folate-mediated targeting with improved antitumor activity","[{\"question\":\"What problem does the study address in pancreatic ductal adenocarcinoma treatment?\",\"answer\":\"PDAC has limited effective therapies and a poor prognosis, largely because the dense desmoplastic tumor microenvironment obstructs drug delivery and supports rapid progression. The work targets this barrier by developing a targeted nanodrug system.\"},{\"question\":\"How is TRAM@PPF designed to improve targeted delivery?\",\"answer\":\"TRAM@PPF uses PLGA nanoparticles modified with PEG2000-FA (folate) to deliver the KCa3.1 channel inhibitor TRAM-34, aiming for folate-mediated tumor targeting and improved uptake in PDAC cells.\"},{\"question\":\"What efficacy outcomes are reported in vitro and in vivo?\",\"answer\":\"In vitro, TRAM@PPF inhibits cell proliferation and enhances apoptosis. After intravenous dosing in pancreatic cancer mouse models, it significantly reduces tumor growth and tumor weight and prolongs survival, while showing excellent biosafety.\"}]","Evaluation of TRAM@PPF Nanoparticles for Efficacy Against Pancreatic Cancer in Mice Model | PDF",1790092713,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04747bf815e170a349c4f6f8d5d0cb3d.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d489bb6b8dc198c24a8f22984b8303d.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9fc7d13927fe534f4504574f93bcfd67.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d44d3a80a041ca5bda54df72ba155e7.webp",980,1268]